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PMyocardial Infarction
yperglycemia Is an Important
redictor of Impaired Coronary
low Before Reperfusion Therapy in
T-Segment Elevation Myocardial Infarction
orik R. Timmer, MD,* Jan Paul Ottervanger, MD, PHD,* Menko-Jan de Boer, MD, PHD, FACC,*
an-Henk E. Dambrink, MD, PHD,* Jan C. A. Hoorntje, MD, PHD,* A. T. Marcel Gosselink, MD, PHD,*
arry Suryapranata, MD, PHD,* Felix Zijlstra, MD, PHD, FACC,† Arnoud W. J. van’t Hof, MD, PHD,*
n behalf of the Zwolle Myocardial Infarction Study Group
wolle and Groningen, the Netherlands
OBJECTIVES This study was designed to investigate whether elevated glucose is associated with impaired
Thrombolysis In Myocardial Infarction (TIMI) flow before primary percutaneous coronary
intervention (PCI).
BACKGROUND Reperfusion before primary PCI in patients with ST-segment elevation myocardial infarction
(STEMI) is associated with an improved outcome. Hyperglycemia in patients with STEMI
is associated with an adverse prognosis. Hyperglycemia may induce a pro-thrombotic state
and therefore be of influence on TIMI flow before PCI.
METHODS A total of 460 consecutive patients with STEMI treated with primary PCI were included in
this analysis. Hyperglycemia was defined as a glucose 7.8 mmol/l (140 mg/dl).
RESULTS Hyperglycemia was observed in 70% and TIMI flow grade 3 before primary PCI in 17% of
the patients. Patients with hyperglycemia less often had TIMI flow grade 3 before primary
PCI (12% vs. 28%, p  0.001). After adjustment for differences in baseline variables,
hyperglycemia was a strong predictor of absence of reperfusion before primary PCI (odds ratio
2.6, 95% confidence interval 1.5 to 4.5).
CONCLUSIONS Hyperglycemia in patients with STEMI is an important predictor of impaired epicardial flow
before reperfusion therapy has been initiated. Investigation of methods improving coronary
flow before primary PCI in these patients is warranted. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.050999–1002) © 2005 by the American College of Cardiology Foundation
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catients with ST-segment elevation myocardial infarction
STEMI) who already have normal Thrombolysis In Myo-
ardial Infarction (TIMI) flow grade 3 of the infarct-related
rtery before primary percutaneous coronary intervention
PCI) have improved left ventricular function, lower inci-
ence of congestive heart failure, and decreased mortality
ompared to patients without initial TIMI flow grade 3
1,2). This background is the basis for facilitated primary
CI, aiming at early reperfusion through administration of
harmaceutic agents before mechanical intervention. Iden-
ification of patients without TIMI flow grade 3 on admis-
ion may provide insight on the mechanism of spontaneous
eperfusion and identify subjects who benefit most from
dditional pharmacologic or mechanical strategies. Hyper-
lycemia during STEMI is associated with an increased
ortality (3). Although hyperglycemia may induce a pro-
hrombotic state, no data with regard to admission glucose
nd initial TIMI flow are present. Therefore we investigated
From the *Department of Cardiology, Isala Klinieken, locatie Weezenlanden,
wolle, the Netherlands; and †Department of Cardiology, Thoraxcenter, University
ospital Groningen, Groningen, the Netherlands.w
Manuscript received October 27, 2004; revised manuscript received December 2,
004, accepted December 13, 2004.hether admission glucose is associated with TIMI flow on
dmission.
ETHODS
atients. This study concerns a post-hoc analysis of the
ngoing Tirofiban in Myocardial Infarction Evaluation
ON-TIME) trial, a randomized controlled trial of tirofiban
ncluding patients with STEMI treated with primary PCI
4). In this trial, before-hospital administration of tirofiban
as compared with administration in the hospital. Inclusion
riteria were the presence of chest pain for more than 30
in together with more than 0.2 mV (anterior myocardial
nfarction) or 0.1 mV (non-anterior myocardial infarction)
T-segment elevation in two contiguous electrocardiogram
eads and the ability to perform primary angioplasty within
h after the start of symptoms. Patients 80 years of age,
omen 50 years of age, patients who were treated with
hrombolytic therapy in the previous 24 h, patients receiving
arfarin or acenocoumarol within the past 7 days, and
atients with a contraindication to glycoprotein IIb/IIIa
lockade were excluded. Patients with severe heart failure or
ardiogenic shock (Killip class III or IV) and patients who
ere receiving hemodialysis were also excluded. All patients
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ntravenously together with 250 mg of aspirin intravenously.
efore transportation, oral informed consent was obtained
n all patients by either a physician or a specialized ambu-
ance crew. The protocol was approved by each institution’s
eview board or ethical committee. Patients were trans-
orted to the catheterization laboratory as soon as possible,
here both coronary arteries were visualized. Percutaneous
oronary intervention was performed with standard tech-
iques if the coronary anatomy was suitable for angioplasty.
fter PCI, all patients were treated with tirofiban (mainte-
ance infusion, 0.15 g/kg/min) for 24 h, clopidogrel (300
g loading dose followed by 75 mg daily for one month),
spirin, beta-blockade, statin therapy and angiotensin-
onverting enzyme inhibition. Baseline characteristics, clin-
cal data, angiographic data, and outcomes were recorded
rospectively in a dedicated database.
easurements and definitions. Core laboratory analysts
DIAGRAM, Zwolle, the Netherlands) who were unaware
f the clinical history and outcome of the patients assessed
IMI flow quantitatively according to the TIMI classifica-
ion (5). Hyperglycemia was defined as glucose levels on
dmission of 7.8 mmol/l (140 mg/dl) (whole blood:
odular system, Roche Analytics, Mannheim, Germany)
Table 1. Baseline Characteristics of the Patien
Normoglyce
<7.8 mmo
(<140 mg/
(n  138
Age (yrs) 58.9  10
Male gender 120 (87%
Risk factors (%)
Diabetes mellitus 2 (1%)
Hypertension 34 (25%
Family history 60 (44%
Hypercholesterolemia 36 (26%
Smoking 98 (73%
Heart rate (beats/min) 75  20
Blood pressure (mm Hg)
Systolic  100 10 (8%)
Diastolic  60 11 (9%)
Ischemic time  SD 228  14
Ischemic time  3 h 44 (37%
Coronary history
Previous AMI 10 (7%)
Previous CABG* 3 (2%)
Previous PCI 10 (7%)
Multi-vessel disease 65 (47%
Anterior infarction 63 (46%
Abbreviations and Acronyms
OR  odds ratio
PCI  percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial InfarctionComparison of proportions was done by chi-square analysis, excep
AMI  acute myocardial infarction; CABG  coronary arterys stated by the American Diabetes Association (6). Diabe-
es was defined as a history of diabetes on admission with
he use of oral hypoglycemic agents or insulin.
tatistical analysis. Differences between group means at
aseline were assessed with the two-tailed Student t test.
hi-square analysis was used to test differences between
roportions. When the expected frequency of a variable was
5, the Fisher exact test was used. To study independent
redictors of TIMI flow, multivariate logistic regression
nalysis was performed comparing TIMI flow grade 3 with
IMI flow grade 0 to 2. To exclude confounding effects of
iabetes, additional stratified analyses were performed, with
eparate analyses in patients without diabetes. Statistical
ignificance was considered a two-tailed p value0.05. The
tatistical Package for the Social Sciences (SPSS Inc.,
hicago, Illinois) version 10.1 was used for all statistical
nalysis.
ESULTS
aseline characteristics. The ON-TIME trial included
07 patients with STEMI treated with primary PCI.
dmission glucose was measured in 477 patients (94%), and
IMI flow before primary PCI was scored in 487 patients
96%). In 460 (91%) patients both admission glucose and
IMI flow was present and these patients were included in
he final analysis. A TIMI flow grade 3 before primary PCI
as present in 76 patients (17%). These patients were
ounger (58.9 11.7 years vs. 62.1 10.2 years, p 0.01),
ere more often smokers (77% vs. 63%, p  0.02), and less
ften had anterior infarction (31% vs. 49%, p  0.01).
atients were divided into groups with normoglycemia (n
ups According to Presence of Hyperglycemia
Hyperglycemia
>7.8 mmol/l
(>140 mg/dl)
p Value(n  322)
62.3  10.3 0.001
249 (77%) 0.02
44 (14%) 0.001
93 (29%) 0.35
125 (39%) 0.39
67 (21%) 0.22
200 (63%) 0.04
72  19 0.13
34 (12%) 0.27
47 (16%) 0.05
217  83 0.32
120 (40%) 0.59
27 (8%) 0.67
8 (3%) 1.00
15 (5%) 0.26
172 (53%) 0.73
145 (46%) 0.92t Gro
mia
l/l
dl)
)
.7
)
)
)
)
)
3
)
)
)t when stated otherwise. *Calculated with Fisher exact test.
bypass graft; PCI  percutaneous coronary intervention.
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April 5, 2005:999–1002 Hyperglycemia and Poor Initial Epicardial Flow38) and with hyperglycemia (n  322). Baseline charac-
eristics are shown in Table 1. Hyperglycemic patients were
lder (p  0.001), were more often women (p  0.02), and
ore often had diabetes (p  0.001) compared with
atients with normoglycemia. The prevalence of a Killip
lass 1 was comparable between the patient groups.
lucose levels and TIMI flow. Patients with hyperglyce-
ia less often had TIMI flow grade 3 before primary PCI
ompared with patients without hyperglycemia (12% vs.
8%, p  0.001). A TIMI flow grade of 0 to 1 before
rimary PCI was more often present in patients with
yperglycemia (Table 2). With decreasing TIMI flow be-
ore primary PCI, the percentage of patients with hypergly-
emia increased (TIMI flow grade 3  50%, TIMI flow
rade 2 67%, TIMI flow grade 0 to 1 76%). In patients
ithout diabetes, hyperglycemia was also associated less
ften with TIMI flow grade 3 before PCI (11% vs. 27%, p
0.001). No differences in TIMI flow grade 3 before
rimary PCI were present between patients with and
ithout diabetes (p  0.86). We divided the patient group
nto quartiles according to their admission glucose. The
resence of TIMI flow grade 3 on admission was 28.7%,
4.4%, 13.8%, and 10.2%, respectively, in the lowest to the
ighest quartile.
ultivariate analysis. Multivariate analysis was performed
o investigate whether hyperglycemia on admission was
ndependently associated with TIMI flow before primary
CI. We included age, gender, and all other variables that
ere significantly different between patients with and with-
ut hyperglycemia (diabetes and smoking). After multivar-
ate analysis, hyperglycemia (odds ratio [OR] 2.6, p 
.001) was an independent predictor of initial TIMI flow
rade 0 to 2 (Table 3). Inclusion of surrogate measures of
hysical stress (heart rate, blood pressure, and Killip class)
id not change these results (OR 2.3; p  0.004). Contin-
ous glucose was also independently associated with initial
IMI flow grade 0 to 2 (OR 1.2 mmol/l, p  0.002).
eparate analyses for hyperglycemia and diabetes revealed
hat only hyperglycemia was independently associated with
nitial TIMI flow. Exclusion of patients with diabetes did
ot influence the association of hyperglycemia with TIMI
ow grade 0 to 2 (OR 2.7; 95% confidence interval 1.5 to
.6, p  0.001).
irofiban administration. There was no influence of early
ersus late administration of tirofiban with regard to initial
IMI flow grade 3 in the total study group (19% vs. 15%,
 0.22). In patients with normal glucose levels, initial
IMI flow grade 3 was nonsignificantly higher after early
reatment with tirofiban (32% vs. 23%, p  0.24), whereas
o association between early treatment and TIMI flow
rade 3 was present in patients with hyperglycemia (13% vs.
1%). In both patients with and without early tirofiban
dministration, there was a significant association between
yperglycemia and, less often, TIMI flow grade 3 on
dmission.
*ISCUSSION
his is the first study to investigate the association between
IMI flow before reperfusion therapy and admission glu-
ose in patients with STEMI. Hyperglycemia was a strong
redictor of the absence of TIMI flow grade 3 of the
nfarct-related vessel before primary PCI. Further investi-
ation with regard to glycometabolic status and initial TIMI
ow should be initiated.
xplanations for the findings. First, patients with reduced
IMI flow may represent a sicker patient population. Stress
s accompanied by high levels of catecholamines such as
ortisol and adrenaline. These hormones increase glycogen-
lysis and lipolysis and reduce insulin sensitivity, resulting in
levated glucose levels (7). Therefore, patients with elevated
lucose levels could represent patients with an increased
esponse to stress, for example owing to more severe
emodynamic compromise or more extensive myocardial
amage. However, after inclusion of systolic and diastolic
lood pressure, heart rate, and Killip class on admission,
yperglycemia was independently associated with TIMI
ow. Another explanation can be prothrombotic properties
ssociated with hyperglycemia. Gresele et al. (8) showed
hat acute hyperglycemia increased platelet activation in
iabetic patients. Nondiabetic patients with hyperglycemia
ay also have increased activation of platelets. Furthermore,
ecent evidence showed that acute hyperglycemia increased
nflammatory responses during STEMI (9,10). As systemic
nflammation is a potent prothrombotic stimulus, promot-
ng procoagulant factors and inhibiting natural anticoagu-
ants, elevation of inflammatory responses in hyperglycemic
ubjects may partly explain our observations with regard to
nitial TIMI flow (11). Although diabetes has been associ-
ted with reduced myocardial reperfusion after STEMI
able 2. Initial TIMI Flow Grade According to Admission
lucose
Glucose
<7.8 mmol/l
(<140 mg/dl)
Glucose
>7.8 mmol/l
(>140 mg/dl) p Value
IMI flow grade 3 38 (28%) 38 (12%) 0.001*
IMI flow grade 2 32 (23%) 65 (20%)
IMI flow grade 1 7 (5%) 42 (13%)
IMI flow grade 0 61 (44%) 177 (55%) 0.03†
As compared to TIMI flow grade 2 to 0. †As compared to TIMI flow grade 1 to 3.
able shows a transition of better initial TIMI flow grade in patients with
ormoglycemia and worse initial TIMI flow grade in those with hyperglycaemia.
TIMI  Thrombolysis In Myocardial Infarction.
able 3. Multivariate Analysis of Initial TIMI Flow Grade 0 to 2
Odds Ratio 95% CI p Value
yperglycemia* 2.6 1.5–4.5 0.001
on-smoking 1.6 0.9–3.0 0.13
ale gender 1.1 0.5–2.1 0.96
ge (per yr) 1.0 0.9–1.0 0.17
iabetes 0.5 0.2–1.3 0.15Hyperglycemia was defined as a glucose level 7.8 mmol/l (140 mg/dl).
CI  confidence interval; TIMI  Thrombolysis In Myocardial Infarction.
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Hyperglycemia and Poor Initial Epicardial Flow April 5, 2005:999–100212), in our study diabetes was not associated with initial
IMI flow. Possibly, acute hyperglycemia is more impor-
ant than chronic hyperglycemia in predicting TIMI flow
efore PCI.
mplications for treatment. The majority of patients
70%) in our analysis were hyperglycemic on admission. In
hese patients, only 12% had TIMI flow grade 3 on
dmission. Whether early reduction of glucose levels
hrough insulin administration improves TIMI flow is
nknown. Treatment with glucose-insulin and potassium
nfusion by this mechanism may be beneficial and should be
urther studied. Resolving this issue would be of interest
rom both a clinical and an experimental point of view.
urthermore, additional pharmacologic interventions to
chieve early adequate TIMI flow should be investigated in
hese patients. Methods of implementing facilitated PCI
hrough early administration of thrombolysis are a topic of
rowing clinical importance. Identification of patients with
bsent or reduced initial TIMI flow may be of help in
electing patients for facilitated PCI. Patients with early
iagnosed hyperglycemia (e.g., in the ambulance) may
enefit from more aggressive treatment before PCI, with
otential use of thrombolytic agents or higher dosage of
lycoprotein IIb/IIIa inhibitors (13). In our study, before-
ospital treatment with a regular dosage of tirofiban was not
ssociated with better TIMI flow in patients with hypergly-
emia. However, analyses of a limited number of patients in
on-prespecified subgroups should be interpreted with
aution.
tudy limitations. Our study involves a subanalysis of a
rior performed trial. As HbA1c levels were not available it
emains unclear whether acute or chronic hyperglycemia is
ost important with regard to initial TIMI flow. Further-
ore, our observation could have been caused by confound-
ng. Patients with reduced TIMI flow before primary PCI
ere older, whereas advanced age was also associated with
yperglycemia. However, after multivariate analysis hyper-
lycemia remained associated with a decreased TIMI flow.
ther unmeasured variables may also be of importance with
egard to initial TIMI flow.
onclusions. Hyperglycemia on admission is an important
redictor of reduced TIMI flow before primary PCI. Fur-her investigation to improve coronary flow of the infarct-
elated artery before mechanistic reperfusion is warranted in
yperglycemic patients.
eprint requests and correspondence: Dr. Arnoud W. J. van’t
of, Department of Cardiology, Isala Klinieken, locatie Weezen-
anden, Groot Wezenland 20, 8011 JW Zwolle, the Netherlands.
-mail: v.r.c.derks@isala.nl.
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